Recursion Pharmaceuticals (RXRX) Scheduled to Post Quarterly Earnings on Thursday

Recursion Pharmaceuticals (NASDAQ:RXRX) will be releasing its earnings data after the market closes on Thursday, May 9th. Analysts expect Recursion Pharmaceuticals to post earnings of ($0.43) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.06. The firm had revenue of $10.89 million during the quarter, compared to the consensus estimate of $12.37 million. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. On average, analysts expect Recursion Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ:RXRX opened at $8.79 on Wednesday. The firm has a market capitalization of $2.06 billion, a PE ratio of -5.67 and a beta of 0.85. Recursion Pharmaceuticals has a 12 month low of $4.92 and a 12 month high of $16.75. The business has a 50-day moving average of $9.76 and a two-hundred day moving average of $9.24.

Analysts Set New Price Targets

RXRX has been the topic of a number of recent research reports. KeyCorp lifted their price target on shares of Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Monday, March 4th. Needham & Company LLC reaffirmed a “buy” rating and set a $17.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 9th. Finally, TD Cowen assumed coverage on Recursion Pharmaceuticals in a research report on Friday, January 26th. They issued a “market perform” rating on the stock. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, Recursion Pharmaceuticals currently has an average rating of “Hold” and an average price target of $12.75.

Insider Activity

In other Recursion Pharmaceuticals news, CFO Michael Secora sold 23,124 shares of the business’s stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of $7.58, for a total value of $175,279.92. Following the transaction, the chief financial officer now owns 1,231,055 shares in the company, valued at approximately $9,331,396.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Recursion Pharmaceuticals news, CFO Michael Secora sold 23,124 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $7.58, for a total transaction of $175,279.92. Following the sale, the chief financial officer now directly owns 1,231,055 shares in the company, valued at approximately $9,331,396.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Tina Marriott sold 8,000 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $14.89, for a total value of $119,120.00. Following the completion of the transaction, the chief operating officer now directly owns 639,982 shares in the company, valued at $9,529,331.98. The disclosure for this sale can be found here. Over the last three months, insiders sold 352,946 shares of company stock worth $3,485,453. 15.75% of the stock is currently owned by company insiders.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.